News headlines about Affymetrix (NASDAQ:AFFX) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Affymetrix earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the scientific and technical instruments company an impact score of 45.8766201160371 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Affymetrix (NASDAQ:AFFX) traded up $0.02 during midday trading on Wednesday, reaching $14.01. 5,030,400 shares of the company’s stock were exchanged, compared to its average volume of 3,494,434. Affymetrix has a 12-month low of $8.28 and a 12-month high of $16.15.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Affymetrix (NASDAQ:AFFX) Share Price” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://stocknewstimes.com/2017/12/06/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-affymetrix-affx-stock-price-3.html.
Affymetrix, Inc (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry.
Receive News & Ratings for Affymetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymetrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.